{"id":10881,"date":"2026-05-26T16:30:00","date_gmt":"2026-05-26T14:30:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=6ca789cbcf28f7db78547c901b1ff84b"},"modified":"2026-05-26T16:30:00","modified_gmt":"2026-05-26T14:30:00","slug":"verastem-oncology-appoints-michael-p-bailey-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=10881","title":{"rendered":"Verastem Oncology Appoints Michael P. Bailey to its Board of Directors"},"content":{"rendered":"

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS\/MAPK pathway-driven cancers, today announced the appointment of Michael P. Bailey<\/a> to its Board of Directors. The Company also announced that Robert Gagnon stepped down from the Board following the end of his term on May 21, 2026.<\/p><\/a><\/a>

\n\u201cWe are excited to have Michael join our Board as he brings more than three decades of experience leading global pharmaceutical and biotechnology companies, with a proven track record of taking oncology medicines from clinical development through successful commercialization, including landmark therapies like ERBITUX\u00ae,\u201d said Daniel Paterson, president and chief executive officer of Verastem Oncology. \u201cWe look forward to drawing on the insight and expertise Michael brings as we enter the next phase of growth for AVMAPKI\u00ae FAKZYNJA\u00ae CO-PACK and advance the development of VS-7375, our potential best-in-class oral KRAS G12D (ON\/OFF) inhibitor.\u201d<\/p>

\n\u201cMichael is an accomplished biopharmaceutical executive with deep expertise across the full product lifecycle. Michael\u2019s perspective will be an asset to our Board as Verastem advances its innovative pipeline and builds on its commercial success,\u201d said John Johnson, chairman of Verastem\u2019s Board of Directors. \u201cWe\u2019d also like to thank Robert for his dedicated service and the contributions he made during his tenure.\u201d<\/p>

\nMr. Bailey added, \u201cI am honored to join Verastem\u2019s Board of Directors at such a pivotal time for the company. Verastem has built a strong business for an underserved rare cancer patient population, and with VS-7375, the company has the potential to make a significant difference in the lives of patients living with KRAS G12D-mutated cancers where there are currently no approved therapies. I look forward to supporting the team and contributing to the company\u2019s continued growth.\u201d<\/p>

\nMichael P. Bailey<\/b><\/p>

\nMr. Bailey currently serves as president and chief executive officer (CEO) of AVEO Pharmaceuticals, Inc. (AVEO), an LG Chem, Ltd. Company, and has served on its Board since January 2015, having previously held the roles of chief business officer and chief commercial officer at AVEO. In 2023, Mr. Bailey led the acquisition of AVEO by LG Chem, Ltd. Before AVEO, he was senior vice president of business development and chief commercial officer at Synta Pharmaceuticals Corp. Earlier, Mr. Bailey spent nine years at ImClone Systems Inc., where he led commercial planning and the launch of ERBITUX\u00ae (cetuximab) across multiple oncology indications, drove new product planning for CYRAMZA\u00ae (ramucirumab) and PORTRAZZA\u00ae (necitumumab) and rose to senior vice president of commercial operations. Prior to ImClone, Mr. Bailey managed the cardiovascular new products development portfolio at Genentech. Mr. Bailey started his career as part of SmithKline Beecham\u2019s executive marketing development program, where he held a variety of commercial roles, including sales, strategic planning and product management. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from Mendoza College of Business at University of Notre Dame and continued his executive education in Finance at Harvard Business School and Board of Director Leadership at Wharton School of Business.<\/p>

\nAbout Verastem Oncology<\/b><\/p>

\nVerastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS\/MAPK pathway-driven cancers. Verastem markets AVMAPKI\u00ae FAKZYNJA\u00ae CO-PACK<\/a> in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF\/MEK inhibition<\/a>, FAK inhibition<\/a>, and KRAS G12D inhibition<\/a>. For more information, please visit www.verastem.com<\/a> and follow us on LinkedIn<\/a>.<\/p> Contacts<\/b>

\nFor Investor and Media Inquiries:<\/b>Julissa Viana\nSenior Vice President, Corporate Communications,\nInvestor Relations & Patient Advocacy\ninvestors@verastem.com<\/a> or\nmedia@verastem.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS\/MAPK pathway-driven cancers, today announced the appointment of Michael P. Bailey to its Board of Director…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10881","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/10881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10881"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/10881\/revisions"}],"predecessor-version":[{"id":10882,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/10881\/revisions\/10882"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}